JP2006522812A - 複素環mchr1アンタゴニスト - Google Patents

複素環mchr1アンタゴニスト Download PDF

Info

Publication number
JP2006522812A
JP2006522812A JP2006509727A JP2006509727A JP2006522812A JP 2006522812 A JP2006522812 A JP 2006522812A JP 2006509727 A JP2006509727 A JP 2006509727A JP 2006509727 A JP2006509727 A JP 2006509727A JP 2006522812 A JP2006522812 A JP 2006522812A
Authority
JP
Japan
Prior art keywords
methyl
compound
mmol
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522812A5 (https=
Inventor
バービアン,ケヴィン,ケイ
カーペンター,アンドリュー,ジェイ
クーパー,ジョエル,ピー
フェルドマン,ポール,エル
グオ,ユ,シー
ハンドロン,アンソニー,エル
ハーツォグ,ドナルド,エル
ハイマン,クリフトン,イー
ピート,アンドリュー,ジェイ
ペッカム,グレゴリー,イー.
スピーク,ジェイソン,ディー.
スウェイン,ウィリアム,アール
タバレス,フランシス,エックス.
チョウ,ウイチャン
ガリード,ドゥルス,エム.
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2006522812A publication Critical patent/JP2006522812A/ja
Publication of JP2006522812A5 publication Critical patent/JP2006522812A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2006509727A 2003-04-11 2004-04-06 複素環mchr1アンタゴニスト Pending JP2006522812A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46229203P 2003-04-11 2003-04-11
PCT/US2004/010518 WO2004092181A1 (en) 2003-04-11 2004-04-06 Heterocyclic mchr1 antagonists

Publications (2)

Publication Number Publication Date
JP2006522812A true JP2006522812A (ja) 2006-10-05
JP2006522812A5 JP2006522812A5 (https=) 2007-01-25

Family

ID=33299933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509727A Pending JP2006522812A (ja) 2003-04-11 2004-04-06 複素環mchr1アンタゴニスト

Country Status (8)

Country Link
US (1) US20060194871A1 (https=)
EP (1) EP1618112A1 (https=)
JP (1) JP2006522812A (https=)
AR (1) AR044011A1 (https=)
CA (1) CA2521832A1 (https=)
MX (1) MXPA05010859A (https=)
TW (1) TW200510429A (https=)
WO (1) WO2004092181A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502957A (ja) * 2007-05-11 2011-01-27 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
JP2017523977A (ja) * 2014-07-28 2017-08-24 ジ インダストリー アンド アカデミック コオペレーション イン チュンハム ナショナル ユニバーシティー(アイエーシー) 新規なインデン誘導体、その調製方法、及びそれを有効成分として含有する網膜疾患を予防又は処置するための医薬組成物
JP2020518661A (ja) * 2017-07-19 2020-06-25 シャンドン ルーナン リサーチ インスティテュート オブ コール ケミカル エンジニアリング アンド テクノロジーShandong Lunan Research Institute of Coal Chemical Engineering and Technology ベンゾイミダゾール系化合物およびその製造方法
JP2023520924A (ja) * 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調節するための化合物及び方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5000490B2 (ja) * 2005-04-28 2012-08-15 武田薬品工業株式会社 チエノピリミドン化合物
WO2007011285A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
AU2006292119A1 (en) * 2005-09-23 2007-03-29 3M Innovative Properties Company Method for 1H-imidazo[4,5-c]pyridines and analogs thereof
ATE429428T1 (de) 2005-09-30 2009-05-15 Hoffmann La Roche Indanderivate als antagonisten des mch-rezeptors
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
AR056155A1 (es) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
WO2007093364A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX2008015486A (es) * 2006-06-08 2009-01-12 Lilly Co Eli Nuevos receptores antagonistas de la hormona concentrador de melanina (mch).
EA015127B1 (ru) * 2006-06-08 2011-06-30 Эли Лилли Энд Компани Антагонисты мсн-рецепторов
US20070299062A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Melanin concentrating hormone antagonists
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
JP2010501553A (ja) * 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Mchr1アンタゴニストとしてのチエノピリミジン−4−オン誘導体およびチエノピリダジン−7−オン誘導体
NZ578096A (en) 2007-01-10 2011-11-25 Albany Molecular Res Inc 5-pyridinone substituted indazoles
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
EP2848621A4 (en) * 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
KR102494596B1 (ko) * 2014-07-31 2023-01-31 재단법인 한국파스퇴르연구소 2-아미노-벤즈이미다졸 유도체 및 5-리폭시게나아제 및/또는 프로스타글란딘 e 합성효소 억제제로서의 이들의 용도
CN106866545B (zh) * 2017-03-31 2019-07-09 枣庄学院 1-环烷烃-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法
CN109020895B (zh) * 2018-08-07 2020-04-24 枣庄学院 一种金属催化的1-苄胺基取代苯并咪唑的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082925A1 (en) * 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2002006245A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082925A1 (en) * 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2002006245A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502957A (ja) * 2007-05-11 2011-01-27 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
JP2017523977A (ja) * 2014-07-28 2017-08-24 ジ インダストリー アンド アカデミック コオペレーション イン チュンハム ナショナル ユニバーシティー(アイエーシー) 新規なインデン誘導体、その調製方法、及びそれを有効成分として含有する網膜疾患を予防又は処置するための医薬組成物
US10501473B2 (en) 2014-07-28 2019-12-10 The Industry & Academic Cooperation In Chungnam National University (Iac) Fused heterocyclic ring compounds and method of treating retinal disease using same
JP2020518661A (ja) * 2017-07-19 2020-06-25 シャンドン ルーナン リサーチ インスティテュート オブ コール ケミカル エンジニアリング アンド テクノロジーShandong Lunan Research Institute of Coal Chemical Engineering and Technology ベンゾイミダゾール系化合物およびその製造方法
JP2023520924A (ja) * 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調節するための化合物及び方法
JP7797407B2 (ja) 2020-04-08 2026-01-13 リミックス セラピューティクス インコーポレイテッド スプライシングを調節するための化合物及び方法

Also Published As

Publication number Publication date
WO2004092181A1 (en) 2004-10-28
WO2004092181A9 (en) 2005-01-27
MXPA05010859A (es) 2005-12-14
AR044011A1 (es) 2005-08-24
US20060194871A1 (en) 2006-08-31
EP1618112A1 (en) 2006-01-25
CA2521832A1 (en) 2004-10-28
TW200510429A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
JP2006522812A (ja) 複素環mchr1アンタゴニスト
EP1442025B1 (en) Pyrimidinones as melanin concentrating hormone receptor 1
JP7817170B2 (ja) 小分子stingアンタゴニスト
CA2312885C (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
CA2740262C (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
US20100056515A1 (en) Benzimidazole compounds
CZ281511B6 (cs) Benzimidazolonové deriváty jako 5-HT1A a 5-HT2 antagonisté
WO2023057414A1 (en) Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
KR20140014173A (ko) 오렉신 길항제로서 유용한 신규 피라졸 및 이미다졸 유도체
CN107406428B (zh) Fyn激酶抑制剂
JP2010528037A (ja) 5−ht6受容体親和性を有する4’置換化合物
JP2010519226A (ja) 5−ht6受容体親和性を有する6’位置換インドール及びインダゾール誘導体
CA2417082C (en) New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US20170239237A1 (en) Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
WO2000055143A1 (en) Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
JP4887368B2 (ja) 新規ヘテロ環化合物
KR20240046742A (ko) 소분자 sting 길항제
US7285557B2 (en) Pyrimidinones as melanin concentrating hormone receptor 1
KR102653543B1 (ko) 알파2c 길항제로서의 2-(1-헤테로아릴피페라진-4-일)메틸-1,4-벤조디옥산 유도체
AU2002335004A1 (en) Pyrimidinones as melanin concentrating hormone receptor 1
HK1158647B (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100907